Pacific Biosciences of California Stock Forecast, Price & News

+0.48 (+1.52 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume2.07 million shs
Average Volume1.96 million shs
Market Capitalization$6.38 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PACB News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter.

Pacific Biosciences of California logo

About Pacific Biosciences of California

Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. The firm's products and services include PacBio sequel system, consumables, analytical software and single molecule real-time (SMRT) compatible products. It operates through the following geographical segments: North America, Europe and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

2.13 out of 5 stars

Analyst Opinion: 3.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions

Is Pacific Biosciences of California a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Pacific Biosciences of California stock.
View analyst ratings for Pacific Biosciences of California
or view top-rated stocks.

What stocks does MarketBeat like better than Pacific Biosciences of California?

Wall Street analysts have given Pacific Biosciences of California a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Pacific Biosciences of California wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Pacific Biosciences of California's next earnings date?

Pacific Biosciences of California is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Pacific Biosciences of California

How can I listen to Pacific Biosciences of California's earnings call?

Pacific Biosciences of California will be holding an earnings conference call on Tuesday, August 3rd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California, Inc. (NASDAQ:PACB) issued its earnings results on Tuesday, February, 9th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.43 by $0.06. The biotechnology company had revenue of $27.10 million for the quarter, compared to analyst estimates of $25.54 million. Pacific Biosciences of California had a negative trailing twelve-month return on equity of 43.06% and a negative net margin of 64.25%. The company's quarterly revenue was up 41.9% compared to the same quarter last year.
View Pacific Biosciences of California's earnings history

How has Pacific Biosciences of California's stock been impacted by COVID-19 (Coronavirus)?

Pacific Biosciences of California's stock was trading at $3.44 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PACB stock has increased by 834.6% and is now trading at $32.15.
View which stocks have been most impacted by COVID-19

What guidance has Pacific Biosciences of California issued on next quarter's earnings?

Pacific Biosciences of California updated its second quarter 2021 earnings guidance on Tuesday, July, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $30.50 million-$30.50 million, compared to the consensus revenue estimate of $29.89 million.

What price target have analysts set for PACB?

4 analysts have issued 12 month target prices for Pacific Biosciences of California's stock. Their forecasts range from $15.00 to $62.00. On average, they expect Pacific Biosciences of California's stock price to reach $43.50 in the next twelve months. This suggests a possible upside of 35.3% from the stock's current price.
View analysts' price targets for Pacific Biosciences of California
or view top-rated stocks among Wall Street analysts.

Who are Pacific Biosciences of California's key executives?

Pacific Biosciences of California's management team includes the following people:
  • Christian O. Henry, President, Chief Executive Officer & Director
  • Mark David Van Oene, Chief Operating Officer
  • Susan G. Kim, Chief Financial Officer
  • Stephen W. Turner, Chief Technology Officer
  • Jonas Korlach, Chief Scientific Officer

What is Christian Henry's approval rating as Pacific Biosciences of California's CEO?

2 employees have rated Pacific Biosciences of California CEO Christian Henry on Christian Henry has an approval rating of 100% among Pacific Biosciences of California's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Pacific Biosciences of California's key competitors?

What other stocks do shareholders of Pacific Biosciences of California own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA).

What is Pacific Biosciences of California's stock symbol?

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Who are Pacific Biosciences of California's major shareholders?

Pacific Biosciences of California's stock is owned by many different institutional and retail investors. Top institutional shareholders include Alliancebernstein L.P. (0.12%), Archford Capital Strategies LLC (0.04%), Carnegie Capital Asset Management LLC (0.02%), Compagnie Lombard Odier SCmA (0.01%) and IFP Advisors Inc (0.00%). Company insiders that own Pacific Biosciences of California stock include Eric Schaefer, James Michael Phillips, Kathy Ordonez, Lucy Shapiro, Michael Hunkapiller, Susan K Barnes and William W Ericson.
View institutional ownership trends for Pacific Biosciences of California

Which major investors are buying Pacific Biosciences of California stock?

PACB stock was acquired by a variety of institutional investors in the last quarter, including Compagnie Lombard Odier SCmA, Carnegie Capital Asset Management LLC, Alliancebernstein L.P., Archford Capital Strategies LLC, and IFP Advisors Inc.
View insider buying and selling activity for Pacific Biosciences of California
or or view top insider-buying stocks.

How do I buy shares of Pacific Biosciences of California?

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacific Biosciences of California's stock price today?

One share of PACB stock can currently be purchased for approximately $32.15.

How much money does Pacific Biosciences of California make?

Pacific Biosciences of California has a market capitalization of $6.38 billion and generates $78.89 million in revenue each year. The biotechnology company earns $29.40 million in net income (profit) each year or ($0.43) on an earnings per share basis.

How many employees does Pacific Biosciences of California have?

Pacific Biosciences of California employs 147,000 workers across the globe.

When was Pacific Biosciences of California founded?

Pacific Biosciences of California was founded in 2004.

What is Pacific Biosciences of California's official website?

The official website for Pacific Biosciences of California is

Where are Pacific Biosciences of California's headquarters?

Pacific Biosciences of California is headquartered at 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025.

How can I contact Pacific Biosciences of California?

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at (650) 521-8000 or via email at [email protected]

This page was last updated on 7/31/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.